TY - JOUR
T1 - Antidepressant use in Denmark, Germany, Spain, and Sweden between 2009 and 2014
T2 - Incidence and comorbidities of antidepressant initiators
AU - Forns, Joan
AU - Pottegård, Anton
AU - Reinders, Tammo
AU - Poblador-Plou, Beatriz
AU - Morros, Rosa
AU - Brandt, Lena
AU - Cainzos-Achirica, Miguel
AU - Hellfritzsch, Maja
AU - Schink, Tania
AU - Prados-Torres, Alexandra
AU - Giner-Soriano, Maria
AU - Hägg, David
AU - Hallas, Jesper
AU - Cortés, Jordi
AU - Jacquot, Emmanuelle
AU - Deltour, Nicolas
AU - Perez-Gutthann, Susana
AU - Pladevall, Manel
AU - Reutfors, Johan
N1 - Funding Information:
Anton Pottegård reports participation in research projects funded by Alcon, Almirall, Astellas, Astra-Zeneca, Novo Nordisk, LEO Pharma, and Servier, all with funds paid to the institution where he was employed (no personal fees) and with no relation to the work reported in this paper.Jesper Hallas has participated in research projects funded by Novartis, Pfizer, Menarini, MSD, Nycomed, Leo Pharmaceuticals, Almirall, Servier, Astellas, and Alkabello with grants paid to the institution where he was employed. He has personally received fees for teaching or consulting from the Danish Association of Pharmaceutical Manufacturers and from Pfizer and Menarini.The agomelatine post-authorisation study was funded by Les Laboratoires Servier under a contract granting independent publication rights to the research team. The present manuscript was funded by internal resources at each institution.
Funding Information:
Johan Reutfors, David Hägg, and Lena Brandt are employees of the Centre for Pharmacopidemiology, which receives grants from several entities (pharmaceutical companies, regulatory authorities, contract research organisations) for the performance of drug safety and drug utilisation studies.
Funding Information:
Anton Pottegård reports participation in research projects funded by Alcon , Almirall , Astellas , Astra-Zeneca , Novo Nordisk , LEO Pharma , and Servier , all with funds paid to the institution where he was employed (no personal fees) and with no relation to the work reported in this paper.
Publisher Copyright:
© 2019
PY - 2019/4/15
Y1 - 2019/4/15
N2 - Background: We aimed to describe patterns of use and characteristics of 10 commonly used antidepressants for the period 2009–2014 in Denmark, Germany, Spain, and Sweden. Methods: Adult initiators from 2009 to 2014 of each study antidepressant were identified in four countries using five data sources: the Danish National registers, GePaRD (Germany), EpiChron (Aragon, Spain), SIDIAP (Catalonia, Spain), and the Swedish National Registers. The study included 10 study antidepressants: citalopram, escitalopram, fluoxetine, paroxetine, sertraline, duloxetine, venlafaxine, amitriptyline, mirtazapine, and agomelatine. Results: Citalopram was the most prescribed study antidepressant, followed by mirtazapine. Paroxetine and agomelatine were the least prescribed antidepressants. Mirtazapine was widely used among older antidepressant initiators with higher percentages of comorbidities at baseline, and fluoxetine was used among young patients. Citalopram and amitriptyline had the lowest percentage of multiple antidepressant use in the 12 months prior to the current treatment episode, while agomelatine, duloxetine, and venlafaxine had the highest percentage of multiple antidepressant use in the year prior to the current treatment episode. Limitations: The most important limitations are exposure information based on filled prescriptions, focus on antidepressant initiators only, lack of information on the indication, and heterogeneity of the type of data across data sources. Conclusions: Results of this study including 4.8 million study antidepressant initiators of study antidepressants suggest that citalopram and mirtazapine are the most commonly prescribed antidepressants. Agomelatine and paroxetine were the least used antidepressants in the participating populations. Mirtazapine was the antidepressant most commonly prescribed among older antidepressant initiators with high percentage of comorbidities at baseline, whereas fluoxetine was commonly used among young patients.
AB - Background: We aimed to describe patterns of use and characteristics of 10 commonly used antidepressants for the period 2009–2014 in Denmark, Germany, Spain, and Sweden. Methods: Adult initiators from 2009 to 2014 of each study antidepressant were identified in four countries using five data sources: the Danish National registers, GePaRD (Germany), EpiChron (Aragon, Spain), SIDIAP (Catalonia, Spain), and the Swedish National Registers. The study included 10 study antidepressants: citalopram, escitalopram, fluoxetine, paroxetine, sertraline, duloxetine, venlafaxine, amitriptyline, mirtazapine, and agomelatine. Results: Citalopram was the most prescribed study antidepressant, followed by mirtazapine. Paroxetine and agomelatine were the least prescribed antidepressants. Mirtazapine was widely used among older antidepressant initiators with higher percentages of comorbidities at baseline, and fluoxetine was used among young patients. Citalopram and amitriptyline had the lowest percentage of multiple antidepressant use in the 12 months prior to the current treatment episode, while agomelatine, duloxetine, and venlafaxine had the highest percentage of multiple antidepressant use in the year prior to the current treatment episode. Limitations: The most important limitations are exposure information based on filled prescriptions, focus on antidepressant initiators only, lack of information on the indication, and heterogeneity of the type of data across data sources. Conclusions: Results of this study including 4.8 million study antidepressant initiators of study antidepressants suggest that citalopram and mirtazapine are the most commonly prescribed antidepressants. Agomelatine and paroxetine were the least used antidepressants in the participating populations. Mirtazapine was the antidepressant most commonly prescribed among older antidepressant initiators with high percentage of comorbidities at baseline, whereas fluoxetine was commonly used among young patients.
KW - Antidepressants
KW - Comorbidity
KW - Drug utilization study
KW - Europe
UR - http://www.scopus.com/inward/record.url?scp=85061533836&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061533836&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2019.02.010
DO - 10.1016/j.jad.2019.02.010
M3 - Article
C2 - 30780117
AN - SCOPUS:85061533836
VL - 249
SP - 242
EP - 252
JO - J Affect Disord
JF - J Affect Disord
SN - 0165-0327
ER -